"The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

1 (tie), Lauren Coughlin, Georgia Hall, Minjee Lee, Madelene Sagstrom, Maja Stark and Angel Yin, 2. 7, 33 tied with 1. 1 (tie), Jaravee Boonchant, In Gee Chun, Danielle Kang, Ruixin Liu, Ryann O'Toole ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...